Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review-Reference-Cited by-同舟云学术

Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review

Published:2022-11 Issue:11 Volume:25 Page:
ISSN:1758-2652
Container-title:Journal of the International AIDS Society
language:en
Short-container-title:J Int AIDS Soc.

Author:

Townsend Claire L.¹,O'Rourke John¹,Milanzi Edith²,Collins Intira Jeannie²^ORCID,Judd Ali²^ORCID,Castro Hannah²,Vicari Marissa³,Jesson Julie⁴^ORCID,Leroy Valériane⁴^ORCID,Renaud Françoise⁵^ORCID,Penazzato Martina⁵^ORCID

Affiliation:

1. Consultants to the World Health Organization Geneva Switzerland

2. MRC Clinical Trials Unit at UCL University College London London UK

3. International AIDS Society Geneva Switzerland

4. Center for Epidemiology and Research in POPulation Health (CERPOP), Inserm, Université de Toulouse Université Paul Sabatier Toulouse France

5. HIV Department World Health Organization Geneva Switzerland

Funder

World Health Organization

International AIDS Society

Publisher

Wiley

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jia2.25970

Reference50 articles.

1. UNAIDS. UNAIDS Fact Sheet.2021(cited 2022 Jan 15).https://www.unaids.org/en/resources/fact‐sheet.

2. Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir

3. Genetic barrier to resistance for dolutegravir;Llibre JM;AIDS Rev,2015

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biktarvy for the treatment of HIV infection: Progress and prospects;Biochemical Pharmacology;2023-11

2. Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications;The Journal of Clinical Endocrinology & Metabolism;2023-07-12

3. Virologic Outcomes and ARV Switch Profiles 2 Years After National Rollout of Dolutegravir to Children Less Than 15 Years in Southern Mozambique;Pediatric Infectious Disease Journal;2023-07-06